Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Next Previous
Search
Trial Profile

A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPLORE-306
  • Sponsors Eisai Inc

    • Most Recent Events

    • 01 Sep 2021 Results assessing efficacy and safety of adjunctive perampanel coadministered with levetiracetam across four Phase III Studies (304, 305, 306 and 335) in patients aged greater or equal to 12 years with focal-onset seizures presented at the 34th International Epilepsy Congress
    • 01 Sep 2021 Results of post hoc analysis (n=1387) assessing TEAE rates with perampanel by treatment period in patients aged greater than equal to 12 - less than 18 and greater than 18 years from NCT00699972, NCT00699582, NCT00700310, NCT01618695 and NCT01393743 studies, presented at the 34th International Epilepsy Congress.
    • 01 Sep 2021 Results of post-hoc analysis of four studies (Studies 304/305/306/335) and their open-label extensions (Studies 307/335) were presented at the 34th International Epilepsy Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top